%0 Journal Article %1 Kontovinis.2009 %A Kontovinis, L. F. %A Papazisis, K. T. %A Touplikioti, P. %A Andreadis, C. %A Mouratidou, D. %A Kortsaris, A. H. %D 2009 %J BMC.Cancer %K Carcinoma Gastrointestinal Medical Oncology Plasma Population Stromal Tumors Tyrosine analysis methods protein response %P 82 %T Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers %U PM:19284623 %V 9 %X BACKGROUND: Sunitinib is a protein tyrosine kinase-inhibitor targeting VEGFR, c-kit and PDGFR. It has been approved for the treatment of metastatic renal-cell carcinoma and gastrointestinal stromal tumors. Although it has been shown to prolong disease-free and overall survival in renal-cell carcinoma patients, only 70% of the treated population receive a clinical benefit (CB) from the treatment. Markers that could predict clinical benefit to sunitinib would be an important aid in monitoring and following their treatment. We assessed the outcome and plasma proangiogenic factors in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib in our institution. METHODS: We have treated 42 patients with metastatic clear-cell renal carcinoma with sunitinib. Plasma concentrations of VEGF-A, sVEGFR2 and PDGF were determined by ELISA. RESULTS: At the time of analysis 39 patients were evaluable for response and 30 patients had obtained a clinical benefit (CB). Median progression

@article{Kontovinis.2009, abstract = {BACKGROUND: Sunitinib is a protein tyrosine kinase-inhibitor targeting VEGFR, c-kit and PDGFR. It has been approved for the treatment of metastatic renal-cell carcinoma and gastrointestinal stromal tumors. Although it has been shown to prolong disease-free and overall survival in renal-cell carcinoma patients, only 70% of the treated population receive a clinical benefit (CB) from the treatment. Markers that could predict clinical benefit to sunitinib would be an important aid in monitoring and following their treatment. We assessed the outcome and plasma proangiogenic factors in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib in our institution. METHODS: We have treated 42 patients with metastatic clear-cell renal carcinoma with sunitinib. Plasma concentrations of VEGF-A, sVEGFR2 and PDGF were determined by ELISA. RESULTS: At the time of analysis 39 patients were evaluable for response and 30 patients had obtained a clinical benefit (CB). Median progression}, added-at = {2010-02-05T11:28:39.000+0100}, author = {Kontovinis, L. F. and Papazisis, K. T. and Touplikioti, P. and Andreadis, C. and Mouratidou, D. and Kortsaris, A. H.}, biburl = {https://www.bibsonomy.org/bibtex/29d920341793c101386b66105f81eef53/kanefendt}, interhash = {2ee202fcb7d01435af29edb6f52d4746}, intrahash = {9d920341793c101386b66105f81eef53}, journal = {BMC.Cancer}, keywords = {Carcinoma Gastrointestinal Medical Oncology Plasma Population Stromal Tumors Tyrosine analysis methods protein response}, pages = 82, timestamp = {2010-02-05T11:28:51.000+0100}, title = {Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers}, url = {PM:19284623}, volume = 9, year = 2009 }